News
Boston and beyond: Stay connected at #AACE2018
No one is immune from the pull of colleagues past, present, and even future. Here’s how to make the most of networking at AACE 2018.
News
AACE 2018: A dream team of presenters
An array of potentially practice-enhancing presentations at AACE 2018.
News
Original research expands at AACE 2018
With more than 1,000 abstracts, this year’s meeting of the American Association of Clinical Endocrinologists is breaking records
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
Video
ODYSSEY Outcomes results build on FOURIER
ODYSSEY Outcomes proves benefit of PCSK9 inhibition, but small differences from FOURIER are concerning.
News
Post-ACS death lowered in ODYSSEY Outcomes
ORLANDO – Mortality and major adverse cardiovascular events were cut 15%, but that’s not all.
News
ACC Day 3: Finishing strong in Late-Breaking Clinical Trial Sessions
Barbershops and anticoagulant reversal agents: ACC 18 vice chair Andrew Kates, MD, highlights two late-breakers.
News
ACC Day 2: Late-Breaking Clinical Trial highlights
Long-term outcomes of a novel heart pump and a look at what happens when copays go away, will be revealed on Sunday.
News
ACC Late-Breaking Clinical Trial sessions preview for day 1
Saturday features reports on two highly anticipated trials, ODYSSEY and VEST.
News
Poststroke depression raises risk of cerebrovascular death 35-fold
Depression after a stroke is deadly and should be monitored and treated.
News
Novel agent to be studied in relapsed/refractory AML
The phase 1b/2 trial will study a polo-like kinase 1 inhibitor.
News
Start with fitness when deciding on treatment for elderly AML patients
In this difficult-to-treat population, fitness assessments help.
News
Late-Breaking Science preview: Wednesday, Nov. 15
Wednesday at AHA is worth sticking around for, if you like innovation.